2017 Top Stories in RCC: CheckMate-214
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591-597.
- Escudier B, Tannir NM, McDermott DF, et al. Checkmate 214: Efficacy and safety of nivolumab + ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. Paper presented at: ESMO 2017 Congress; September 8–12, 2017; Madrid, Spain. Abstract LBA5.
- Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study [published online July 5, 2015]. J Clin Oncol. DOI: 10.1200/JCO.2016.72.1985.
Disclosure statements are available on the authors' profiles: